Wilate granted orphan drug exclusivity approval for von Willebrand disease (VWD)

Octapharma AG announced that it has received orphan drug exclusivity approval for wilate (double virus inactivated von Willebrand Factor/Coagulation Factor VIII concentrate [human]) for the treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as in patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated.

Wilate is expected to be available in early 2010.

For more information call (201) 604-1130 or visit www.octapharma.com.